Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Pact Is Affirmation Of Affimed Technology

Executive Summary

Beware the hype but a deal with one of the big oncology players that involves $96m upfront and potentially $5.0bn in milestones is a decent validation for the German biotech's technology platform.

You may also be interested in...



Affimed’s AFM13 Data Show Potential Of NK Cell Approach

Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.

Deal Watch: Affimed Teams Up In Immuno-Oncology With Roivant, Artiva

German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.

Biopharma Quarterly Dealmaking Statistics, Q3 2018

Biopharma financing reached $14.6 billion in the third quarter, a 15% increase over Q2, while merger and acquisitions, at $7.7 billion (the lowest quarter of the year so far), showed a sharp decline. Alliance value reached $20.3 billion, far exceeding the $13.8 billion from Q2.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC123751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel